Zobrazeno 1 - 10 of 16 pro vyhledávání: '"Luuk van Hooren"'
2
Akademický článek
Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma
Autor: Luuk van Hooren, Alessandra Vaccaro, Mohanraj Ramachandran, Konstantinos Vazaios, Sylwia Libard, Tiarne van de Walle, Maria Georganaki, Hua Huang, Ilkka Pietilä, Joey Lau, Maria H. Ulvmar, Mikael C. I. Karlsson, Maria Zetterling, Sara M. Mangsbo, Asgeir S. Jakola, Thomas Olsson Bontell, Anja Smits, Magnus Essand, Anna Dimberg
Publikováno v: Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Agonistic CD40 antibodies (αCD40) have broad immunostimulatory properties, however their efficacy in glioma remains unclear. Here the authors show that αCD40 promotes the formation of tertiary lymphoid structures but does not improve survival and i
Externí odkaz: https://doaj.org/article/960c23767579410eb75556847b8c9b3f
Zobrazit plný text záznamu
3
Akademický článek
Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations.
Autor: Iliana K Kerzeli, Martin Lord, Milena Doroszko, Ramy Elgendy, Aikaterini Chourlia, Ivan Stepanek, Elinor Larsson, Luuk van Hooren, Sven Nelander, Per-Uno Malmstrom, Anca Dragomir, Ulrika Segersten, Sara M Mangsbo
Publikováno v: PLoS ONE, Vol 16, Iss 7, p e0253178 (2021)
Bladder cancer, one of the most prevalent malignancies worldwide, remains hard to classify due to a staggering molecular complexity. Despite a plethora of diagnostic tools and therapies, it is hard to outline the key steps leading up to the transitio
Externí odkaz: https://doaj.org/article/e72af935bcd64a5e8cdbce8747ad3c19
Zobrazit plný text záznamu
4
Akademický článek
Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy
Autor: Maria Georganaki, Mohanraj Ramachandran, Sander Tuit, Nicolás Gonzalo Núñez, Alexandros Karampatzakis, Grammatiki Fotaki, Luuk van Hooren, Hua Huang, Roberta Lugano, Thomas Ulas, Aura Kaunisto, Eric C Holland, Peter Ellmark, Sara M Mangsbo, Joachim Schultze, Magnus Essand, Sonia Tugues, Anna Dimberg
Publikováno v: OncoImmunology, Vol 9, Iss 1 (2020)
CD40-stimulating immunotherapy can elicit potent anti-tumor responses by activating dendritic cells and enhancing T-cell priming. Tumor vessels orchestrate T-cell recruitment during immune response, but the effect of CD40-stimulating immunotherapy on
Externí odkaz: https://doaj.org/article/4a2116d5ba7b4f129b0b2715b4654949
Zobrazit plný text záznamu
5
Akademický článek
Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
Autor: Maria Georganaki, Luuk van Hooren, Anna Dimberg
Publikováno v: Frontiers in Immunology, Vol 9 (2018)
Boosting natural immunity against malignant cells has had a major breakthrough in clinical cancer therapy. This is mainly due to the successful development of immune checkpoint blocking antibodies, which release a break on cytolytic anti-tumor-direct
Externí odkaz: https://doaj.org/article/04f1dbeacdaf4a47b926c625c93a7b6e
Zobrazit plný text záznamu
9
ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma
Autor: Anna Dimberg, Bàrbara Laviña, Maria Georganaki, Lei Liu Conze, Hua Huang, Luuk van Hooren, Kalyani Vemuri, Tiarne van de Walle, Liqun He, Lei Zhang, Roberta Lugano, Mohanraj Ramachandran, Peetra U. Magnusson, Fredrik Pontén, Christer Betsholtz, Michael Bergqvist, Elisabetta Dejana, Anja Smits
Publikováno v: Neuro Oncol
Background Tumor vessels in glioma are molecularly and functionally abnormal, contributing to treatment resistance. Proteins differentially expressed in glioma vessels can change vessel phenotype and be targeted for therapy. ELTD1 (Adgrl4) is an orph
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::810ec56d98bdf9c70cf044019567adcd
https://pubmed.ncbi.nlm.nih.gov/35015881
Zobrazit plný text záznamu
10
Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma
Autor: Anna Dimberg, Konstantinos Vazaios, Thomas Olsson Bontell, Hua Huang, Mikael C. I. Karlsson, Alessandra Vaccaro, Maria Georganaki, Tiarne van de Walle, Maria Zetterling, Asgeir Store Jakola, Magnus Essand, Sylwia Libard, Anja Smits, Sara M. Mangsbo, Mohanraj Ramachandran, Joey Lau, Luuk van Hooren, Maria H. Ulvmar, Ilkka Pietilä
Publikováno v: Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Gliomas are brain tumors characterized by an immunosuppressive microenvironment. Immunostimulatory agonistic CD40 antibodies (αCD40) are in clinical development for solid tumors, but are yet to be evaluated for glioma. Here, we demonstrate that syst
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2c7bcaca1373ab46811cd5db7910491
http://europepmc.org/articles/PMC8257767
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje